Skip Navigation LinksHome > December 2002 - Volume 25 - Issue 6 > Phase II Trial of Paclitaxel-Epirubicin in Patients With Rec...
American Journal of Clinical Oncology:

Phase II Trial of Paclitaxel-Epirubicin in Patients With Recurrent Soft-Tissue Sarcoma.

Pivot, Xavier; Chevreau, Christine; Cupissol, Didier; Lortholary, Alain; Bui, Nguyen-Binh; Eymard, Jean-Christophe; Bay, Jacques-Olivier; Baranzelli, Marie-Christine; Mita, Monica; Barnouin, Laurence; Savary, Jacqueline; Thyss, Antoine

Collapse Box


Twenty-seven patients with recurrent soft-tissue sarcoma (STS) entered a multicenter study to determine the efficacy of the combination paclitaxel 200 mg/m2 and epirubicin 75 mg/m2 administered every 21 days. Patient characteristics included the following: 14 women and 13 men, median age of 52 years, 12 patients had local recurrence and 20 had metastasis. Eighteen patients had previously received chemotherapy for recurrent disease. The main grade III to IV hematologic toxicities were neutropenia (70%), anemia (3.7%), and thrombocytopenia (7.4%). Febrile neutropenia occurred in 5 patients (18.5%). Severe nonhematologic toxicities were rare. Two patients had a partial response (7.4%; 95% CI: 2.6-12.2%), with a median response duration of 3 and 5 months. Six patients had stable disease (22.2%), and 19 had progressive disease (70.5%). The median overall survival from study inclusion was 8 months. This study suggests the association paclitaxel-epirubicin does not increase the known activity of anthracycline in recurrent STS.

© 2002 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.